Tacrolimus

• Description:

  Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties[1].

• Product Name Alternative:

  FK506; Fujimycin; FR900506

• UNSPSC:

  12352005

• Hazard Statement:

  H301, H361, H372

• Target:

  Antibiotic; Autophagy; Bacterial; FKBP; Phosphatase

• Type:

  Natural Products

• Related Pathways:

  Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cancer; Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Tacrolimus.html

• Purity:

  99.93

• Solubility:

  DMSO : 125 mg/mL (ultrasonic) |Ethanol : 12.5 mg/mL (ultrasonic)

• Smiles:

  O=C ([C@@] (CCCC1) ([H]) N1C (C ([C@@]2 (O) [C@H] (C) C[C@H] (OC) [C@@] (O2) ([H]) [C@@H] (OC) C[C@@H] (C) C/C (C) =C/[C@H]3CC=C) =O) =O) O[C@H] (/C (C) =C/[C@H]4C[C@@H] (OC) [C@H] (O) CC4) [C@H] (C) [C@@H] (O) CC3=O

• Molecular Formula:

  C44H69NO12

• Molecular Weight:

  804.02

• Precautions:

  H301, H361, H372

• References & Citations:

  [1]Thomson AW, et al. Mode of action of Tacrolimus (FK506) : molecular and cellular mechanisms. Ther Drug Monit. 1995 Dec;17 (6) :584-91.|[2]Vogel KR, et al. mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. J Inherit Metab Dis. 2016 Nov;39 (6) :877-886.|[3]Zhu H, et al. Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF 1α expression in vivo. Mol Med Rep. 2014 Aug;10 (2) :585-92.|[4]Okada Y, et al. Tacrolimus ameliorates dextran sulfate sodium-induced colitis in mice: implication of interleukin-1β suppression. Biol Pharm Bull. 2011;34 (12) :1823-7.|[5]Yuwei He, et al. Drug targeting through platelet membrane-coated nanoparticles for the treatment of rheumatoid arthritis. Nano Res. 30 June 2018.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Natural Products

• Clinical Information:

  Launched

• Isoform:

  Macrolide

• Citation 01:

  ACS Biomater Sci Eng. 2022 Nov 14;8 (11) :4850-4862.|Acta Biomater. 2025 Apr:196:399-409.|Acta Pharmacol Sin. 2024 May 17.|Acta Trop. 2020 Dec;212:105708.|Adv Funct Mater. 2023 Sep 15.|Aging Dis. 2024 Feb 1;15 (1) :282-294.|Am J Dig Dis (Madison) . 2015;2 (2) :95-99.|Am J Transplant. 2023 Mar;23 (3) :336-352.|Animal Model Exp Med. 2023 Jun;6 (3) :255-265.|Antiviral Res. 2023 Jul:215:105618.|Biochim Biophys Acta Gen Subj. 2022 Jun;1866 (6) :130133.|Biochim Biophys Acta Mol Basis Dis. 2025 Apr 21;1871 (6) :167857.|Biomater Sci. 2020 Oct 7;8 (19) :5282-5292.|Biomater Sci. 2023 May 30;11 (11) :4032-4042.|Biomaterials. 2021 May:272:120757.|Biomolecules. 2024 Jun 8;14 (6) :671.|bioRxiv. 2025 February 01.|bioRxiv. 2025 Jul 31:2025.07.30.667742.|bioRxiv. 2025 Nov 20.|BMC Immunol. 2023 Nov 8;24 (1) :43.|BMC Pharmacol Toxicol. 2022 Nov 28;23 (1) :87.|Br J Pharmacol. 2022 Jun;179 (12) :3078-3095.|Brain Res. 2019 May 15:1711:68-76.|Burns Trauma. 2025 Feb 17:13:tkaf007.|Cancer Lett. 2024 Jul 1:593:216841.|Cell Biol Toxicol. 2022 Jun;38 (3) :487-504.|Cell Commun Signal. 2021 Oct 11;19 (1) :103.|Cell Mol Biol Lett. 2024 May 14;29 (1) :72.|Cell Prolif. 2023 Oct;56 (10) :e13460.|Cell Rep. 2021 Jul 20;36 (3) :109404.|Cell Signal. 2025 Sep 8:136:112116.|Cell Syst. 2018 Apr 25;6 (4) :424-443.e7.|Clin Transl Sci. 2025 Feb;18 (2) :e70152.|Developments and Experiments in Health and Medicine. 2025.|Dis Model Mech. 2019 Jan 28;12 (1) . pii: dmm036830. |Drug Deliv. 2021 Dec;28 (1) :1759-1768.|Elife. 2023 MAy 19.|Exp Hematol Oncol. 2016 Jul 29:5:22.|FASEB J. 2023 Feb;37 (2) :e22749.|FASEB J. 2025 Apr 15;39 (7) :e70496.|Food Funct. 2023 Jul 31;14 (15) :7176-7194.|Hepatobiliary Pancreat Dis Int. 2024 Aug;23 (4) :344-352.|Hepatobiliary Surg Nutr. 2023 Dec 1;12 (6) :835-853.|Hong Kong Polytechnic University. 2023 Apr.|Indiana University. 2025.|Insect Sci. 2024 Jun;31 (3) :759-772.|Int Immunopharmacol. 2025 Sep 8:165:115459.|Int J Biol Macromol. 2024 Aug 3:134478.|Int J Biol Sci. 2024 Oct 7;20 (14) :5415-5435.|Int J Mol Sci. 2022 Aug 19;23 (16) :9376.|Int J Mol Sci. 2024 Feb 21;25 (5) :2503.|Int J Pharm. 2019 Dec 13;575:118951.|Int J Pharm. 2025 Jan 20:125247.|Int J Physiol Pathophysiol Pharmacol. 2015 Mar 20;7 (1) :54-60. |Invest Ophthalmol Vis Sci. 2023 Jan 3;64 (1) :19.|J Agric Food Chem. 2025 Jun 18;73 (24) :14985-15002.|J Cell Sci. 2019 May 20;132 (10) :jcs227777.|J Colloid Interface Sci. 2023 Jan 15;630 (Pt A) :676-687.|J Control Release. 2020 Dec 10;328:237-250.|J Extracell Vesicles. 2019 Dec 27;9 (1) :1709262.|J Nanobiotechnology. 2025 Feb 4;23 (1) :81.|J Neurochem. 2022 Dec;163 (5) :419-437.|J Pharm Biomed Anal. 2023 Oct 25:235:115652.|J Toxicol Sci. 2024;49 (8) :337-348.|J Vet Med Sci. 2023 Mar 30;85 (4) :443-446.|Mater Design. 2023 Nov, 235, 112415.|Mater Today Bio. 2024 Apr 22:101061.|Mediators Inflamm. 2019 Dec 17;2019:4176974.|Mol Med Rep. 2022 May;25 (5) :160.|Nano Lett. 2019 Jan 9;19 (1) :124-134.|Nano Res. 11, 6086-6101 (2018) .|NPJ Regen Med. 2022 Sep 2;7 (1) :43.|Patent. US20180263995A1.|Patent. US20220087984A1.|Pathol Res Pract. 2025 Aug:272:156095.|Pharmacol Res. 2021 Feb:164:105382.|Preprints. 2025 Sep 24.|Proc Natl Acad Sci U S A. 2021 Jan 12;118 (2) :e2009539118.|Res Sq. 2024 Aug 13:rs.3.rs-4656461.|Research Square Preprint. 2020 Dec.|Seoul National University. 2033.|Signal Transduct Target Ther. 2023 Nov 1;8 (1) :417.|Skelet Muscle. 2020 Apr 22;10 (1) :10.|Theranostics. 2018 Jan 1;8 (4) :878-893.|Theranostics. 2020 May 16;10 (14) :6483-6499. |Theranostics. 2021 Mar 5;11 (10) :5045-5060.|Theranostics. 2022 Jan 16;12 (4) :1621-1638.|Toxins. 2019 Jun 18;11 (6) :349.|Transpl Immunol. 2021 Oct:68:101434.|Ultrasound Med Biol. 2023 Jul;49 (7) :1647-1657.|Wound Repair Regen. 2023 Jul-Aug;31 (4) :489-499.|Fundam Res. 2024 Mar 19.|SSRN. 2023 Oct 31.|Toxics. 2024 Aug 19;12 (8) :607.|Vaccines. 2024 Sep 29;12 (10) :1117.

• CAS Number:

  104987-11-3